STING1 and glioblastoma: Berger et al. evaluated the status of STING signaling in glioblastoma (GBM) tissues and investigated the immunomodulatory effects of the STING agonist ADU-S100 (synthetic cyclic dinucleotide -CDN) on the brain tumors microenvironment (TME) [48].